Announced Fri, 24 Jul · 10:06 IST
Kwality Pharma gets CDSCO nod for Pembroluzimab preclinical batches
KPL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+1.2%1-day move
₹2673.50
prior close
₹2684.00
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.7+2.0+1.4+1.1+1.2—————————
Up moveDown movePending
AI summary
Kwality Pharmaceuticals has received CDSCO approval to manufacture pilot batches of Pembroluzimab, a biosimilar candidate, for preclinical studies. This marks the transition of the product from the R&D stage to the pre-clinical stage. KPL aims to be among the first generic manufacturers to launch this product after the reference product's patent expiry, subject to successful development and further regulatory approvals. No financial details or timelines were disclosed.
Likely market impact
Positive sentiment for the biologics pipeline, but still early-stage with no near-term revenue impact. Key milestones ahead.